OPTIM (#783)
Laufzeit: 01.01.2018 - 31.12.2021
imported
Kurzfassung
A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (OPTIM)
Laufzeit: 01.01.2018 - 31.12.2021
A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (OPTIM)